MTE #31: Use of Hepatitis C Virus Positive Donor Organs in Hepatitis C Virus Uninfected Solid Organ Transplant Recipients (Ticketed)

Nov 18 2024
Convention Center: Room 33 C
7:00 AM - 7:45 AM
Ticketed Event

World Class Speakers

David S. Goldberg, MD, MSCE
Discussion Leader

David S. Goldberg, MD, MSCE

University of Miami
Jennifer Price, MD, PhD
Discussion Leader

Jennifer Price, MD, PhD

UCSF

Description

Using high-risk donors, including those who are infected with HCV, is a strategy to increase organ supply. The use of direct-acting antiviral therapy has paved the way for the use of HCV-viremic organs, changing the landscape of solid organ transplantation (SOT). Experts in this session review and discuss the data on the use of HCV-infected donor organs in SOT.  



 

Journey Maps

Objectives

  • Review and discuss the use of HCVpositive donor organs in HCVuninfected recipients in solid organ transplant (SOT).
  • Describe the challenges and ethical considerations regarding the use of HCV-positive organs in HCV-uninfected recipients.
  • Discuss the challenges and facilitators to implementing use of HCV-positive donor organs in HCV-uninfected SOT recipients as standard of care.
  • Review the positions of professional societies on the use of HCV-viremic donor organs in HCV-uninfected recipients.